Bafna Pharmaceuticals Ltd. (NSE: BAFNAPH, BSE: 532989) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,141 Cr, it ranks #1,511 by market cap among the 6,197 Indian listed companies on FinBizNet, and #23 of 63 in Pharmaceuticals. At ₹482.05 (as of 16 Nov 2026), the share price is 3.9% below its 52-week high of ₹501.65 and 386.1% above its 52-week low of ₹99.16. The share price is up 190.0% over one year and up 83.3% over three months.
| Current Price | ₹482.05 |
|---|---|
| Market Cap | ₹1,141 Cr |
| NSE Symbol | BAFNAPH |
| BSE Code | 532989 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 104.9 |
| Return on Equity | 12.27% |
| Return on Assets | 4.02% |
| 52-Week Range | ₹99.16 – ₹501.65 |
| 1-Year Price Change | +190.0% |
| 3-Month Price Change | +83.3% |
| Beta (1Y) | -0.46 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.bafnapharma.com |
| Revenue | ₹48 Cr |
|---|---|
| Net Profit | ₹7 Cr |
| Net Margin | 14.4% |
| EPS (Basic) | ₹2.89 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bafna Pharmaceuticals Ltd. reported revenue of ₹48 Cr in Q2 FY27, up 34.4% from ₹35 Cr in Q2 FY26 and up 79.3% from ₹27 Cr in Q1 FY27. It posted a net profit of ₹7 Cr for the quarter, against a net profit of ₹3 Cr in Q2 FY26 (up 119.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹27 Cr (Q1 FY27) to ₹48 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹48 Cr | ₹7 Cr | 14.4% |
| Q1 FY27 | ₹27 Cr | ₹0 Cr | 0.3% |
| Q4 FY26 | ₹42 Cr | ₹3 Cr | 6.5% |
| Q3 FY26 | ₹38 Cr | ₹2 Cr | 4.8% |
| Q2 FY26 | ₹35 Cr | ₹3 Cr | 8.8% |
| Q1 FY26 | ₹35 Cr | ₹3 Cr | 9.8% |
| Q4 FY25 | ₹39 Cr | ₹1 Cr | 3.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 75.00% of Bafna Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
1. Pharmaceutical Formulations-This segment manufactures finished pharmaceutical formulations.
1. Manufacturing of Pharmaceuticals Formations,-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Bafna Pharmaceuticals Ltd. | ₹1,141 Cr | 104.9 | 12.27% | ₹48 Cr | +190.0% |
Listed by market capitalisation. Ratios are shown for context only.
Bafna Pharmaceuticals Ltd. is trading at ₹482.05, with a market capitalisation of ₹1,141 Cr.
Bafna Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Bafna Pharmaceuticals Ltd. has a P/E of 104.9 and a return on equity of 12.27%.
Bafna Pharmaceuticals Ltd. is listed on the NSE under the symbol BAFNAPH and on the BSE under the scrip code 532989.
Bafna Pharmaceuticals Ltd.'s share price is up 190.0% over one year and up 83.3% over three months. Its 52-week range is ₹99.16 to ₹501.65.
In Q2 FY27, Bafna Pharmaceuticals Ltd. reported revenue of ₹48 Cr and net profit of ₹7 Cr, with basic EPS of ₹2.89 (standalone, parsed from the company's exchange filing).
Bafna Pharmaceuticals Ltd. reported revenue of ₹48 Cr in Q2 FY27, up 34.4% from ₹35 Cr in Q2 FY26 and up 79.3% from ₹27 Cr in Q1 FY27.
Promoters held 75.00% of Bafna Pharmaceuticals Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.